Onkologie. 2024:18(1):68-73 | DOI: 10.36290/xon.2024.014
Long-term good-quality survival in a young man with metastatic pancreatic cancer pretreated with gemcitabine + nab-paclitaxel regimen achieved with nal-IRI + 5-FU/LV combination therapy
- Onkologická klinika, FN Ostrava
Pancreatic cancer is a disease with high mortality rates, often detected at late stage. Surgical resection is the only curative treatment, and the outcomes are improved by adjuvant chemotherapy. In patients with an advanced finding, the FOLFIRINOX regimen or the doublet gemcitabine + nab-paclitaxel are recommended in the first-line of palliative treatment; in the second-line, following the gemcitabine-based treatment, nal-IRI (pegylated liposomal irinotecan) + 5-fluorouracil (5-FU) + leucovorin (LV), or the regimen with 5-FU are recommended; and following the therapy with 5-FU, gemcitabine in monotherapy or in combination. New results presented at the 2023 ESMO Congress showed that, in the first-line of palliative treatment, the doublet gemcitabine + nab-paclitaxel had a greater benefit than the FOLFIRINOX regimen. We report a case of a 50-year-old man with progression of pancreatic cancer after surgical and adjuvant treatment in whom, after failure of gemcitabine + nab-paclitaxel in the first-line of palliative treatment, one-year survival with a good quality of life was achieved with the combination of nal-IRI + 5-FU/LV.
Keywords: pancreatic cancer, FOLFIRINOX, gemcitabine, pegylated liposomal irinotecan, case report, GENERATE.
Accepted: February 22, 2024; Published: February 28, 2024 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008-2020.
Go to original source... 
Go to PubMed... - Modrá kniha České onkologické společnosti. Platnost od 1. 3. 2023. Dostupné na: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/.
- Ohba A, et al. Nab-paklitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase 2/3 trial. ESMO Congress 2023, Abstract 16160. Go to original source...
- Triplet therapy does not outperform doublet treatment first line in metastatic pancreatic cancer. Q&A discussion during the Proffered Paper Session 2 - Gastrointestinal tumours, upper digestive, at the ESMO Congress 2023 (Madrid, Spain, 20-24 October). Available from: https://dailyreporter.esmo.org/esmo-congress-2023/gastrointestinal-cancers/triplet-therapy-does-not-outperform-doublet-treatment-first-line-in-metastatic-pancreatic-cancer.
- Conroy T, Pfeiffer P, Vilgrain V, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(11):987-1002. Go to original source... Go to PubMed...
- NCCN Guidelines. Pancreatic adenocarcinoma. Version 1. 2024. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455.
- Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020;38(27): 3217-3230. Go to original source... Go to PubMed...
- Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78-87. Go to original source... Go to PubMed...